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Abstract: Neuroblastoma is the most common and deadly solid tumor in children, and there 
is  currently  no  effective  treatment  available  for  neuroblastoma  patients.  The  repressor 
element-1 silencing transcription (REST) factor has been found to play important roles in 
the  regulation  of  neural differentiation and tumorigenesis. Recently, a REST signature 
consisting of downstream targets of REST has been reported to have clinical relevance in 
both breast cancer and glioblastoma. However it remains unclear how the REST signature 
works  in  neuroblastoma.  Publicly  available  datasets  were  mined  and  bioinformatic 
approaches were used to investigate the utility of the REST signature in neuroblastoma with 
both preclinical and real patient data. The REST signature was found to be associated with drug 
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sensitivity  in  neuroblastoma  cell  lines.  Further,  neuroblastoma  patients  with  enhanced  
REST activity are significantly associated with higher clinical stages. Loss of heterozygosity on 
chromosome 11q23, which occurs in a large subset of high-risk neuroblastomas, tends to be 
correlated  with  high  REST  activity,  with  marginal  significance.  In  conclusion,  the  REST 
signature  has  important  implications  for  targeted  therapy,  and  it  is  a  prognostic  factor  in 
neuroblastoma patients. 
Keywords:  REST;  neuron-restrictive  silencer  factor;  neuroblastoma;  tumor  stage;  drug 
sensitivity; chemotherapeutic target 
 
1. Introduction 
Neuroblastoma is the most common pediatric malignancy in children, accounting for approximately 
15%  of  all  cancer-related  pediatric  deaths  [1–3].  The  mainstay  of  treatment  approaches  includes 
chemotherapy, surgical resection, and radiotherapy [1,4–7]. However, neuroblastoma is remarkably 
heterogeneous.  Many  neuroblastoma  patients  are  resistant  to  chemotherapeutic  drugs  and  develop 
progressive disease [8–10]. For this reason, it is crucial to study the mechanisms of drug resistance and 
to develop effective treatment regimens for patients with neuroblastoma. 
Repressor element-1 silencing transcription (REST) factor is a zinc finger transcription factor that 
modulates a number of genes in neural and non-neural cells [11–13]. It plays critical roles in neural 
differentiation [14,15], and its expression decreases quickly in neural stem cells and is maintained at low 
levels in neurons after differentiation [16]. In neural tumors, REST is expressed at high levels and acts as 
an oncogene [15,16]. Previous studies showed higher REST expression in both human medulloblastoma 
and neuroblastoma tissues than in the adjacent normal brain tissues [17–21]. The high levels of REST in 
patients with medulloblastoma are related to worse overall and event-free survival [18]. To the best of 
our current knowledge, no study has reported any relationship between REST expression and clinical 
outcome in neuroblastoma. 
Recently, a REST signature consisting of downstream targets of REST has been reported to have 
clinical relevance in both breast cancer and glioblastoma [17,22]. However, the use of a REST signature 
for neuroblastoma has not been investigated. In the present study, the utility of REST signature was 
assessed  in  cell  lines  and  human  patient  data.  This  paper  demonstrates  that  the  REST  signature  
applied well in both cell lines and neuroblastoma patients. The REST signature was associated with 
chemo-sensitivity  for  ABT.263  and  Sunitinib,  and  chemo-resistance  for  17-AAG  (also  named 
Tanespimycin, potent heat shock protein 90 inhibitor) and Temsirolimus. Patients exhibiting more REST 
activity were significantly associated with higher tumor stage (p = 0.028). Patients with more REST 
activity were also marginally associated with loss of heterozygosity (LOH) in 11q23 (p = 0.051), which 
is related to malignant evolution of a large subset of neuroblastomas [23–25]. Int. J. Mol. Sci. 2014, 15  11222 
 
2. Results and Discussion 
2.1. Results 
2.1.1. Repressor Element-1 Silencing Transcription (REST) Score in Neuroblastoma 
Neuroblastoma  samples  showed  dynamic  REST  activity  in  both  cell  lines  and  neuroblastoma 
patients. Based on the published REST signature, the expression of the targets was extracted using 
public datasets. The 24 REST gene signatures were reported previously [17]. However, not every gene’s 
measurements were included in the microarray data used in this study. Of the 24 genes, only 17 were 
available in cell line data and only 14 in patient data (Tables 1 and 2). There were two probes for gene 
SCAMP5 shown in Table 2. Usually expression values from different probes for the same gene were 
not averaged due to the difference of probe affinity. Thus, we kept both probes in the calculation of 
REST score. The Pearson correlations between REST and individual signature genes were compared. 
Most of the genes had negative correlations (Tables 1 and 2). Because REST is a gene silencing factor 
and down-regulates target genes in general, genes positively correlated with REST did not confer 
repression regulation by REST [11,16]. For this reason, they were excluded from further analysis. In 
order to derive a summary of the signature genes, a summary statistic was calculated for each sample as 
the standardized average of the target expression. The REST score was here defined as the summary 
statistic  multiplied  by  −1  so  that  a  higher  score  corresponded  to  a  stronger  REST  activity  for 
interpretation  purposes.  This  REST  score  was  used  to  establish  REST  activity  by  leveraging  the 
expression of REST targets. As shown in Figure 1A, there was a subset of neuroblastoma cell lines with 
low REST activity and another subset of samples with high REST activity. The same pattern was also 
observed in tumor samples (Figure 1B). The target genes were found to differ slightly between cell line 
and tumor samples. Some genes were only present in one data set or the other. The regulation by REST 
varied between cell line and tumor samples. For example, CPLX2 was negatively correlated with REST 
expression (Pearson correlation −0.59) in tumor samples but it had a positive correlation to REST in cell 
lines (Pearson correlation 0.05). In general, more REST targets were negatively correlated to REST 
expression in cell lines than tumor samples because the REST signature was developed from cell  
line data [17]. 
Table  1.  Correlation  of  repressor  element-1  silencing  transcription  (REST)  and  REST 
signature genes in neuroblastoma cell lines. 
Symbol  Correlation  p Value 
AP3B2  −0.40135  0.030935 
BSN  −0.3463  0.065728 
CHGB  −0.39356  0.034663 
CPLX2  0.051692  0.790004 
HBA1  0.359446  0.055481 
HBA2  0.090065  0.642199 
KCNB1  −0.40135  0.030936 
MAPK8IP2  −0.19656  0.306799 
MMP24  0.240233  0.209381 Int. J. Mol. Sci. 2014, 15  11223 
 
Table 1. Cont. 
Symbol  Correlation  p Value 
PGBD5  −0.41019  0.027101 
RTN2  −0.30055  0.113145 
SCAMP5  −0.23286  0.224127 
SCGB1D2  −0.42984  0.019953 
SNAP25  −0.39209  0.03541 
STMN3  −0.21973  0.252092 
SYP  −0.2474  0.195705 
VGF  0.018048  0.925965 
Table 2. Correlation of REST and REST signature genes in neuroblastoma tissue. 
Symbol  Probe ID  Correlation  p Value 
AP3B2  38937_at  0.121623  0.22567 
BSN  33728_at  −0.19752  0.047712 
CHGB  33426_at  0.001979  0.984333 
CPLX2  33084_at  −0.59139  7.43 × 10
−11 
KCNB1  40693_at  0.112516  0.262606 
MAPK8IP2  37588_s_at  0.227915  0.02189 
MMP24  32924_at  0.364921  0.000175 
RTN2  34408_at  0.120774  0.228953 
RUNDC3A  36823_at  0.12448  0.214878 
SCAMP5  37545_at  −0.03147  0.754758 
SCAMP5  37546_r_at  −0.55512  1.70 × 10
−9 
SCGB1D2  32880_at  −0.42044  1.20 × 10
−5 
SYP  37182_at  0.103264  0.304127 
SNAP25  38484_at  −0.06155  0.540931 
VGF  32969_r_at  −0.10574  0.292595 
2.1.2. REST Signature and Drug Sensitivity in Neuroblastoma 
Next, the association between the REST signature and drug sensitivity was assessed. The REST score 
was calculated for each cell line and the Spearman’s rank correlation and p value were computed with 
IC50 values. To account for multiple testing, the Beta-Uniform Mixture (BUM) model was used to 
estimate the false discovery rate (FDR) [26]. When there is no significant association after correcting 
for multiple testing, the BUM fit would be dominated by the uniform component and the histogram of 
p values would be flat. Figure 2 showed the fitted BUM model where the Beta component (i.e., the 
superimposed  green  line)  indicated  that  there  were  more  significant  associations  than  one  would 
expect  by  chance.  Table  3  showed  the  number  of  significant  associations  under  different  FDR 
(estimated from the BUM model) and corresponding p value cutoffs. Under FDR = 0.05, 9 drugs that 
had significant association with REST score. The REST score effectively stratified the cell lines into 
chemo-sensitive and chemo-resistant groups with respect to several drugs. As shown in Figure 3A,B, 
17-AAG and Temsirolimus were more effective in cell lines with higher REST activity than in those 
with lower REST activity (ρ = −0.661, p = 0.0003; ρ = −0.624, p = 0.0015). In contrast, Figure 3C,D Int. J. Mol. Sci. 2014, 15  11224 
 
showed that cell lines with higher REST activity tended to be more resistant to ABT.163 treatment that 
inhibited genes in the BCL-2 family (ρ = 0.447, p = 0.0252), and Sunitinib targeting PDGFRA was also 
more sensitive to the cell lines with low REST scores (ρ = 0.431, p = 0.0451). Many other drugs were 
found to have distinct effects on cell lines with various levels of REST activity (Supplementary Figure 
S1A–V). The differential drug sensitivity between REST active and REST inactive cell lines suggested 
that effective therapeutics might be developed based on the REST signature genes. 
Figure 1. Repressor element-1 silencing transcription (REST) signature in neuroblastoma 
cell lines and tumor samples.  (A) Gene expression of the 12 REST targets negatively 
correlated  with  REST  expression  was  observed  for  29  autonomic  ganglia  cell  lines.  
The average expression value of the 12 REST targets multiplied by −1 was used as the 
REST score in cell line data. The samples (columns) were ordered based on REST score; and 
(B) In 101 neuroblastoma patient samples, 7 REST targets were negatively correlated with 
REST expression, and the REST score was computed similarly as in the cell line data. 
A
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Figure 1. Cont. 
 
Table 3. False discovery rate (FDR) table for association between REST score and IC50 in 
cell line data. 
FDR  Number of Significant Associations  p Value Cutoff 
0.05  9  0.00389 
0.10  14  0.01904 
0.15  24  0.04820 
B Int. J. Mol. Sci. 2014, 15  11226 
 
Figure 2. Beta-Uniform Mixture fit for the p values associating IC50 values of 138 drugs  
and the REST score that was used to estimate FDR for controlling multiple testing. The 
superimposed blue line indicated the distribution of p values one would expect when there 
were no associations. In contrast, the superimposed green line indicated distribution of   
p values from this analysis. There were more small p values than one would expect from 
random data indicating a strong association between IC50 and REST score. 
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Figure 3. REST signature was used to stratify neuroblastoma cell lines into chemo-sensitive 
and chemo-resistant groups. (A,B) Cell lines with higher REST scores were more sensitive 
to 17-AAG and Temsirolimus treatment; (C,D) Cell lines with lower REST scores were 
more sensitive to ABT.263 and Sunitinib treatment. 
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2.1.3. REST Signature and Tumor Stage in Neuroblastoma 
Besides the predictive value in chemotherapy among the cell lines, the REST signature was also 
found to be associated with patient clinical covariates. Figure 4 showed that neuroblastoma patients in 
late stage (stage IV) had higher REST activity (ANOVA test p value = 0.0275) than those in early stages 
(Stages I and III combined). This observation was consistent with previous findings in glioblastoma, 
where increased REST activity was associated with poor survival [22]. However, the trend was opposite 
in breast cancer where poor prognosis was found to be associated with decreased REST activity [17]. 
This opposing association between REST and patient outcome might originate from the different roles 
of REST in different tumors. In neural tumors, REST is an oncogene but in carcinomas of the breast, 
lung, and colon it acts as a tumor suppressor [15,16]. 
Previous studies have demonstrated that neuroblastoma patients with MYCN (N-myelocytomatosis 
oncogene) amplification were at more advanced disease stages [27–30]. MYCN is the first amplified 
oncogene  that  was  found  to  be  of  clinical  significance  due  to  its  association  with  aggressive 
neuroblastoma phenotypes. MYCN has been proven to be critical to stimulation of neuroblastoma 
growth. Targeted overexpression of MYCN in transgenic mice causes spontaneous development of 
neuroblastomas [29]. It is therefore important to determine whether MYCN amplification is associated 
with REST activity. Here, a positive trend was found between MYCN amplification and REST score, 
though the p value was not significant (data not shown). The relationship between REST and the LOH 
status  of  11q23,  commonly  found  in  MYCN  unamplified  high-risk  neuroblastomas,  was  also  
assessed [23–25]. Results suggested that REST activity was marginally associated with the LOH in 
11q23 (p value = 0.0514) (Supplementary Figure S2). Int. J. Mol. Sci. 2014, 15  11228 
 
Figure 4. Clinical relevance of the REST signature in neuroblastoma patients. Patients in 
late stage (stage IV) had higher REST scores (ANOVA test p value = 0.0275) than those in 
early stages. Of note, there were no Stage II patients in this cohort. 
tTest p Value: 0.0275
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2.2. Discussion 
REST, also called neuron-restrictive silencer factor (NRSF), plays opposing roles in neoplasia. In 
neural cells and neural tumors, REST is an oncogene, but in carcinomas of the breast, lung, and colon it 
shows anti-oncogenic activity [11–13]. The REST gene is bound to over 2000 genes in neural and 
non-neural cells, but not all of these genes are governed by REST in every cell type [16,31]. REST 
signature genes were detected in three different cell lines transfected with anti-REST shRNA, including 
human embryonic kidney-293, mammary epithelial MCF10, and T-47D cell line. The 24 common 
downstream target genes were up-regulated at least twofold upon REST knockdown in these three cell 
lines [17]. In the present study, 17 of the 24 REST signature genes were available in neuroblastoma  
cell line data and 15 of them were in data from 101 patients with neuroblastoma. Of these, 12 REST 
signature  genes  in  cell  lines  and  7  REST  signature  genes  in  patients  were  negatively  correlated  
with  REST  gene  expression.  Because  the  original  REST  signature  genes  were  not  derived  from 
neuroblastomas, not all of them showed any negative correlation with the REST expression in the 
present  study.  The  lack  of  concordance  between  Tables  1  and  2  might  have  been  caused  by  the 
difference between cell line data and patient data. The cell lines are pure and uncontaminated by 
non-tumor tissue, and patient data from formalin-fixed and paraffin-embedded (FFPE) samples are 
heterogeneous, making it challenging to quantitate patient tissue using gene expression arrays. This 
might also be the reason for the high percentage of genes having negative correlation with REST (12 out 
17 genes in cell lines and 7 out 15 genes in patient data). The different study population and different 
microarray platforms might also alter the correlation between REST and the 24 REST signature genes Int. J. Mol. Sci. 2014, 15  11229 
 
in neuroblastoma. For this reason, thorough studies are planned for further investigation of REST target 
genes in neuroblastoma. 
Previous studies have suggested that histone deacetylase inhibitors may have therapeutic properties 
in patients with REST-positive medulloblastoma [18]. In contrast, glioma patients expressing REST 
signature genes at near-normal and mid-range levels are sensitive to chemotherapy, and REST-enhanced 
glioma  patients  are  refractory  to  multiple  chemotherapeutic  courses  [22].  This  REST-dependent 
chemo-sensitivity may be caused by the interplay between REST target genes and chemotherapeutic 
drugs. Here we discovered that the REST signature could effectively stratify neuroblastoma cell lines 
into chemo-sensitive and chemo-resistant groups. For example, 17-AAG and Temsirolimus were more 
effective in neuroblastoma cell lines with high REST scores. However, ABT.263 and Sunitinib were 
more effective in neuroblastoma cell lines with low REST scores. It might be worthwhile to conduct 
clinic trials for these drug candidates. 
The REST signature might  have potential  prognostic value for clinical outcome. A recent study 
revealed that medulloblastoma patients with high-REST expression had worse overall and disease-free 
survival than patients with REST-negative or REST-minimal tumors based on immuno-histochemical 
analysis [18]. Additionally, studies using siRNA knockdown and bioinformatic analysis demonstrated 
that  the  24  REST  signature  genes  were  related  to  clinical  outcomes  in  both  breast  cancer  and 
glioblastoma [17,22]. In particular, a group of breast cancer patients overexpressing REST signature 
genes  had  worse  prognosis  and  shorter  disease-free survival  than  those  with  low  REST  signature 
expression. Patients in the REST active group were more than twice as likely to undergo recurrence 
within the first 3 years of diagnosis than those in the REST negative group [17]. In more than 30% of 
glioblastomas,  tumor  growth  and  invasive  properties  were  associated  with  higher  levels  of  REST 
expression, and miR-124a, a REST effector, was found to be associated with this REST action [32–34]. 
Previous studies also suggest that patients with REST enhanced glioblastoma had shorter disease free 
survival than non-REST enhanced glioblastoma patients [22]. In neuroblastoma patients, high REST 
scores  were  here  found  to  be  significantly  associated  with  later  tumor  stage.  In  previous  studies, 
although MYCN amplification in neuroblastoma led to poorer clinical outcome, only 40% of high-risk 
neuroblastomas were MYCN-amplified [27,28]. LOH on 11q23 has recently emerged as a critical 
genomic event in the evolution of high-risk neuroblastomas independent of MYCN amplification [23]. 
Similar results were found here: LOH on 11q23 was associated with high REST scores. Recent studies 
also  reported  that  REST  regulates  CD59  expression  in  neuroblastoma,  and  REST  peptides  can   
reduce CD59 expression and so sensitize neuroblastoma to complement-mediated killing triggered by 
anti-GD2  used  in  neuroblastoma  immunotherapy [35].  REST  is  also proposed  to  be an important 
molecular target in the response to retinoic acid treatment for neuroblastoma [19]. In conclusion, the 
current discovery highlighted the clinical importance of REST in brain tumors. The association between 
REST signature and drug response as well as clinical covariates including survival and tumor stage 
suggest that REST might be a good therapeutic target for individualized treatment in brain tumors. Int. J. Mol. Sci. 2014, 15  11230 
 
3. Experimental Section 
3.1. Data Collection 
Cell line gene expression data were downloaded from the Genomics of Drug Sensitivity in Cancer 
website  (http://www.cancerrxgene.org/).  The  expression  was  assayed  using  the  HT  HG  U133A 
platform.  Cell  line  information  (i.e.,  issue  type)  was  downloaded  from  the  COSMIC  database 
(ftp://ftp.sanger.ac.uk/pub/CGP/cell_lines_project/data_export/).  There  were  29  autonomic  ganglia 
samples derived from neuroblastoma patients. Drug sensitivity data for 138 drugs was also downloaded 
from the Genomics of Drug Sensitivity in Cancer website consisting of IC50 estimates. The IC50 value 
was estimated based on a dose-response model that gave the drug concentration needed to kill 50% of 
tumor cells. For the neuroblastoma patient data, 101 tumor samples were downloaded from the Gene 
Expression Omnibus (GEO) under accession number GSE3960 [8]. The risk groups of the patient data 
included low-risk, intermediate-risk, high-risk and high-risk with MYCN amplification, and each group 
contained at least 20 cases. A detailed description of patient characteristics was reported by Wang et al. [8]. 
Clinical  variables  available  through  the  GEO  website  included INSS tumor stage (I, III and IV),  
MYCN amplification status and LOH for specific regions which were assessed in this study. 
3.2. Data Analysis 
Pearson correlations between REST and individual signature gene were computed. To determine 
whether  REST  score  was  associated  with  chemo-sensitivity,  the  Spearman’s  rank  correlation  and  
p value between the IC50 values and REST score were computed. Here the Spearman’s rank correlation 
(ρ) was used due to its robustness to the nonlinear feature of IC50 values. To control for multiple testing, 
the Beta-Uniform Mixture (BUM) model was used and the FDR was estimated  [26]. To assess the 
relevance of REST score to clinical variables, a linear model was applied for continuous covariates and 
the ANOVA test for categorical covariates. All statistical analysis was performed using R software [36]. 
4. Conclusions 
The present study showed that a REST signature plays critical roles in neuroblastoma. It might 
predict drug sensitivity and could be a suitable therapeutic target for individualized treatment. Further, 
neuroblastoma patients with enhanced REST activity are significantly associated with higher clinical 
stage. LOH on chromosome 11q23, which occurs in a large subset of high-risk neuroblastomas, was 
found to correlate with high REST activity, with marginal significance. In this way, the REST signature 
has important implications for chemotherapeutic drug  selection, and it is also a prognostic factor in 
neuroblastoma patients. 
Acknowledgments 
This  study  was  supported  by  The  National  Natural  Science  Foundation  of  China  81173424, 
81271448, 81301092 and the China Postdoctoral Science Foundation 2013M540885. Int. J. Mol. Sci. 2014, 15  11231 
 
Author Contributions 
L.Z. and Y.Y. designed research; J.L., P.T., W.Z. and Y.L. performed research; L.Z., Y.X. and Y.Y. 
analyzed data; and J.L. and P.T. wrote the paper. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References  
1.  Maris, J.M. Recent advances in neuroblastoma. New Engl. J.Med. 2010, 362, 2202–2211. 
2.  Zirath, H.; Frenzel, A.; Oliynyk, G.; Segerström, L.; Westermark, U.K.; Larsson, K.; Persson, M.M.; 
Hultenby,  K.;  Lehtiö,  J.;  Einvik,  C.  MYC  inhibition  induces  metabolic  changes  leading  to 
accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. USA 2013, 110, 10258–10263. 
3.  Stallings, R.L.; Foley, N.H.; Bryan, K.; Buckley, P.G.; Bray, I. Therapeutic targeting of miRNAs in 
neuroblastoma. Expert Opin. Ther.Targets 2010, 14, 951–962. 
4.  Ow,  T.J.;  Bell,  D.;  Kupferman,  M.E.;  Demonte,  F.;  Hanna,  E.Y.  Esthesioneuroblastoma. 
Neurosurg. Clin. N. Am. 2013, 24, 51–65. 
5.  Schipper, M.H.; van Duinen, S.G.; Taphoorn, M.J.; Kloet, A.; Walchenbach, R.; Wiggenraad, R.G.; 
Vecht, C.J. Cerebral ganglioneuroblastoma of adult onset: Two patients and a review of the literature. 
Clin. Neurol. Neurosurg. 2012, 114, 529–534. 
6.  Alisi,  A.;  Cho,  W.C.;  Locatelli,  F.;  Fruci,  D.  Multidrug  resistance  and  cancer  stem  cells  in 
neuroblastoma and hepatoblastoma. Int. J. Mol. Sci. 2013, 14, 24706–24725. 
7.  Krizkova, S.; Fabrik, I.; Huska, D.; Adam, V.; Babula, P.; Hrabeta, J.; Eckschlager, T.; Pochop, P.; 
Darsova, D.; Kukacka, J. An adsorptive transfer technique coupled with Brdicka reaction to reveal 
the importance of metallothionein in chemotherapy with platinum based cytostatics. Int. J. Mol. Sci. 
2010, 11, 4826–4842. 
8.  Wang, Q.; Diskin, S.; Rappaport, E.; Attiyeh, E.; Mosse, Y.; Shue, D.; Seiser, E.; Jagannathan, J.; 
Shusterman,  S.;  Bansal,  M.  Integrative  genomics  identifies  distinct  molecular  classes  of 
neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy 
number. Cancer Res. 2006, 66, 6050–6062. 
9.  Hsu, D.M.; Agarwal, S.; Benham, A.; Coarfa, C.; Trahan, D.N.; Chen, Z.; Stowers, P.N.; Courtney, A.N.; 
Lakoma, A.; Barbieri, E. G-CSF receptor positive neuroblastoma subpopulations are enriched in 
chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013, 73, 
4134–4146. 
10.  Henderson, T.O.; Bhatia, S.; Pinto, N.; London, W.B.; McGrady, P.; Crotty, C.; Sun, C.L.; Cohn, S.L. 
Racial and ethnic disparities in risk and survival in children with neuroblastoma: A children’s 
oncology group study. J. Clin. Oncol. 2011, 29, 76–82. 
11.  Hirabayashi, Y.; Gotoh, Y. Epigenetic control of neural precursor cell fate during development. 
Nat. Rev. Neurosci. 2010, 11, 377–388. Int. J. Mol. Sci. 2014, 15  11232 
 
12.  Li,  H.-T.;  Jiang,  F.-X.;  Shi,  P.;  Zhang,  T.;  Liu,  X.-Y.;  Lin,  X.-W.;  Pang,  X.-N.  In  vitro 
reprogramming of rat bone marrow-derived mesenchymal stem cells into insulin-producing cells 
by genetically manipulating negative and positive regulators. Biochem. Biophys. Res. Commun. 
2012, 420, 793–798. 
13.  Sung, M.; Jeong, M.S.; Jang, S.B. Biological characterization and structure based prediction of 
insulin-like growth factor binding protein-5. Biochem. Biophys. Res. Commun. 2010, 403, 230–236. 
14.  Soldati, C.; Bithell, A.; Johnston, C.; Wong, K.Y.; Teng, S.W.; Beglopoulos, V.; Stanton, L.W.; 
Buckley, N.J. Repressor element 1 silencing transcription factor couples loss of pluripotency with 
neural induction and neural differentiation. Stem Cells 2012, 30, 425–434. 
15.  Majumder, S. REST in good times and bad: roles in tumor suppressor and oncogenic activities.  
Cell Cycle 2006, 5, 1929–1935. 
16.  Negrini, S.; Prada, I.; D’Alessandro, R.; Meldolesi, J. REST: An oncogene or a tumor suppressor? 
Trends Cell Biol. 2013, 23, 289–295. 
17.  Wagoner,  M.P.;  Gunsalus,  K.T.;  Schoenike,  B.;  Richardson,  A.L.;  Friedl,  A.;  Roopra,  A.  
The transcription factor REST is lost in aggressive breast cancer. PLoS Genet. 2010, 6, e1000979. 
18.  Taylor,  P.;  Fangusaro,  J.;  Rajaram,  V.;  Goldman,  S.;  Helenowski,  I.B.;  MacDonald,  T.; 
Hasselblatt, M.; Riedemann, L.; Laureano, A.; Cooper, L. REST is a novel prognostic factor and 
therapeutic target for medulloblastoma. Mol. Cancer Ther. 2012, 11, 1713–1723. 
19.  Singh, A.; Rokes, C.; Gireud, M.; Fletcher, S.; Baumgartner, J.; Fuller, G.; Stewart, J.; Zage, P.; 
Gopalakrishnan,  V.  Retinoic  acid  induces  REST  degradation  and  neuronal  differentiation  
by  modulating  the  expression  of  SCF  (β-TRCP)  in  neuroblastoma  cells.  Cancer  2011,  117, 
5189–5202. 
20.  Fuller, G.N.; Su, X.; Price, R.E.; Cohen, Z.R.; Lang, F.F.; Sawaya, R.; Majumder, S. Many human 
medulloblastoma  tumors  overexpress  repressor  element-1  silencing  transcription  (REST)/ 
neuron-restrictive  silencer  factor,  which  can  be  functionally  countered  by  REST-VP16.  
Mol. Cancer Ther. 2005, 4, 343–349. 
21.  Lawinger,  P.;  Venugopal,  R.;  Guo,  Z.S.;  Immaneni,  A.;  Sengupta,  D.;  Lu,  W.;  Rastelli,  L.;  
Marin  Dias  Carneiro,  A.;  Levin,  V.;  Fuller,  G.N.  The  neuronal  repressor  REST/NRSF  is  an 
essential regulator in medulloblastoma cells. Nat. Med. 2000, 6, 826–831. 
22.  Wagoner,  M.P.;  Roopra,  A.  A  REST  derived  gene  signature  stratifies  glioblastomas  into 
chemotherapy resistant and responsive disease. Biol. Med. Cent. Genomics 2012, 13, 686:1–686:12. 
23.  Guo, C.; White, P.S.; Weiss, M.J.; Hogarty, M.D.; Thompson, P.M.; Stram, D.O.; Gerbing, R.; 
Matthay, K.K.; Seeger, R.C.; Brodeur, G.M. Allelic deletion at 11q23 is common in MYCN single 
copy neuroblastomas. Oncogene 1999, 18, 4948–4957. 
24.  Santo, E.E.; Ebus, M.E.; Koster, J.; Schulte, J.H.; Lakeman, A.; van Sluis, P.; Vermeulen, J.; 
Gisselsson, D.; Ora, I.; Lindner, S. Oncogenic activation of FOXR1 by 11q23 intrachromosomal 
deletion-fusions in neuroblastoma. Oncogene 2012, 31, 1571–1581. 
25.  Yagyu, S.; Iehara, T.; Gotoh, T.; Miyachi, M.; Katsumi, Y.; Kikuchi, K.; Tsuchiya, K.; Osone, S.; 
Kuroda, H.; Sugimoto, T. Preoperative analysis of 11q loss using circulating tumor-released DNA 
in serum: A novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Lett. 2011, 
309, 185–189. Int. J. Mol. Sci. 2014, 15  11233 
 
26.  Pounds,  S.;  Morris,  S.W.  Estimating  the  occurrence  of  false  positives  and  false  negatives  in 
microarray  studies  by  approximating  and  partitioning  the  empirical  distribution  of  p-values. 
Bioinformatics 2003, 19, 1236–1242. 
27.  Cohn, S.L.; Tweddle, D.A. MYCN amplification remains prognostically strong 20 years after its 
“clinical debut”. Eur. J. Cancer 2004, 40, 2639–2642. 
28.  Brodeur, G.M.; Seeger, R.C.; Schwab, M.; Varmus, H.E.; Bishop, J.M. Amplification of N-myc in 
untreated  human  neuroblastomas  correlates  with  advanced  disease  stage.  Science  1984,  224, 
1121–1124. 
29.  Kang, J.H.; Rychahou, P.G.; Ishola, T.A.; Qiao, J.; Evers, B.M.; Chung, D.H. MYCN silencing 
induces differentiation and apoptosis in human neuroblastoma cells. Biochem. Biophys. Res. Commun. 
2006, 351, 192–197. 
30.  Bell, E.; Chen, L.; Liu, T.; Marshall, G.M.; Lunec, J.; Tweddle, D.A. MYCN oncoprotein targets 
and their therapeutic potential. Cancer Lett. 2010, 293, 144–157. 
31.  Otto, S.J.; McCorkle, S.R.; Hover, J.; Conaco, C.; Han, J.J.; Impey, S.; Yochum, G.S.; Dunn, J.J.; 
Goodman, R.H.; Mandel, G. A new binding motif for the transcriptional repressor REST uncovers 
large gene networks devoted to neuronal functions. J. Neurosci. 2007, 27, 6729–6239. 
32.  Conti, L.; Crisafulli, L.; Caldera, V.; Tortoreto, M.; Brilli, E.; Conforti, P.; Zunino, F.; Magrassi, L.; 
Schiffer, D.; Cattaneo, E. REST controls self-renewal and tumorigenic competence of human 
glioblastoma cells. PLoS One 2012, 7, e38486. 
33.  Kamal,  M.M.;  Sathyan,  P.;  Singh,  S.K.;  Zinn,  P.O.;  Marisetty,  A.L.;  Liang,  S.;  Gumin,  J.; 
El-Mesallamy, H.O.; Suki, D.; Colman, H. REST regulates oncogenic properties of glioblastoma 
stem cells. Stem Cells 2012, 30, 405–414. 
34.  Tivnan, A.; Zhao, J.; Johns, T.G.; Day, B.W.; Stringer, B.W.; Boyd, A.W.; Tiwari, S.; Giles, K.M.; 
Teo, C.; McDonald, K.L. The tumor suppressor microRNA, miR-124a, is regulated by epigenetic 
silencing and by the transcriptional factor, REST in glioblastoma. Tumor Biol. 2014, 35, 1459–1465. 
35.  Donev,  R.M.;  Gray,  L.C.;  Sivasankar,  B.;  Hughes,  T.R.;  van  den  Berg,  C.W.;  Morgan,  B.P. 
Modulation  of  CD59  expression  by  restrictive  silencer  factor-derived  peptides  in  cancer 
immunotherapy for neuroblastoma. Cancer Res. 2008, 68, 5979–5987. 
36.  Team,  R.C.  R:  A  Language  and  Environment  for  Statistical  Computing;  R  Foundation  for 
Statistical Computing: Vienna, Austria, 2013. 
©  2014  by  the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 